免疫检查点抑制剂：麻醉医师考虑因素的叙述性综述。
Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist.
机构信息
Department of Anesthesiology & Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Anesthesiology & Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
出版信息
Br J Anaesth. 2020 Mar;124(3):251-260. doi: 10.1016/j.bja.2019.11.034. Epub 2020 Jan 29.
Abstract
Immunotherapy has revolutionised the treatment of oncologic malignancies. Immune checkpoint inhibitors represent a new class of immunotherapy drugs. Although these drugs show promise, they are associated with immune-related adverse reactions. An increasing number of patients who undergo surgery will have had treatment with immune checkpoint inhibitors. In this narrative review article, we discuss their mechanism of action, therapeutic effects, pertinent toxicities, and address specific perioperative considerations for patients treated with immune checkpoint inhibitors.
摘要
免疫疗法已经彻底改变了肿瘤学恶性肿瘤的治疗方法。免疫检查点抑制剂代表了一类新的免疫治疗药物。虽然这些药物显示出了前景，但它们与免疫相关的不良反应有关。越来越多接受手术的患者曾接受过免疫检查点抑制剂治疗。在这篇叙述性综述文章中，我们讨论了它们的作用机制、治疗效果、相关毒性，并针对接受免疫检查点抑制剂治疗的患者提出了具体的围手术期注意事项。
相似文献
1
Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist.免疫检查点抑制剂：麻醉医师考虑因素的叙述性综述。
Br J Anaesth. 2020 Mar;124(3):251-260. doi: 10.1016/j.bja.2019.11.034. Epub 2020 Jan 29.
2
Atypical autoimmune adverse effects with checkpoint blockade therapies.检查点阻断疗法的非典型自身免疫不良反应。
Ann Oncol. 2017 Feb 1;28(2):206-207. doi: 10.1093/annonc/mdw658.
3
Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.综述：使用检查点抑制剂进行癌症免疫治疗的免疫相关不良事件
Arthritis Rheumatol. 2017 Apr;69(4):687-699. doi: 10.1002/art.40043. Epub 2017 Mar 3.
4
New insight in endocrine-related adverse events associated to immune checkpoint blockade.免疫检查点阻断相关内分泌不良事件的新认识。
Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101370. doi: 10.1016/j.beem.2019.101370. Epub 2019 Dec 11.
5
Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.免疫检查点抑制剂的皮肤不良反应：综述概述
Curr Drug Saf. 2019;14(1):14-20. doi: 10.2174/1574886313666180730114309.
6
Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer.免疫检查点抑制剂在老年癌症患者中的疗效和不良反应。
Drugs Aging. 2019 Oct;36(10):927-938. doi: 10.1007/s40266-019-00697-2.
7
Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.免疫检查点抑制剂的皮肤不良反应：皮肤毒性与免疫治疗
Am J Clin Dermatol. 2018 Jun;19(3):345-361. doi: 10.1007/s40257-017-0336-3.
8
Setting the scene - a future 'epidemic' of immune-related adverse events in association with checkpoint inhibitor therapy.背景介绍——免疫相关不良事件伴随检查点抑制剂治疗的未来“流行”。
Rheumatology (Oxford). 2019 Dec 1;58(Suppl 7):vii1-vii6. doi: 10.1093/rheumatology/kez402.
9
Cancer immunotherapy-related adverse events: causes and challenges.癌症免疫治疗相关不良反应：原因与挑战。
Support Care Cancer. 2020 Dec;28(12):6111-6117. doi: 10.1007/s00520-020-05705-5. Epub 2020 Aug 28.
10
Immune Checkpoint Inhibitor Toxicity in 2018.2018年免疫检查点抑制剂毒性
JAMA. 2018 Oct 23;320(16):1702-1703. doi: 10.1001/jama.2018.13995.
引用本文的文献
1
Anesthetic considerations for outpatient interventional radiology procedures for cancer patients.癌症患者门诊介入放射学手术的麻醉注意事项。
Curr Opin Anaesthesiol. 2025 Aug 1;38(4):383-390. doi: 10.1097/ACO.0000000000001515. Epub 2025 May 20.
2
Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy.用于个性化治疗和提高疗效的革命性癌症疗法：克服免疫检查点抑制剂疗法耐药性的策略
Cancers (Basel). 2025 Mar 4;17(5):880. doi: 10.3390/cancers17050880.
3
Immunotherapy-Related Hypophysitis: A Narrative Review.免疫治疗相关垂体炎：一篇叙述性综述
Cancers (Basel). 2025 Jan 27;17(3):436. doi: 10.3390/cancers17030436.
4
The Potential of PD-1 and PD-L1 as Prognostic and Predictive Biomarkers in Colorectal Adenocarcinoma Based on TILs Grading.基于肿瘤浸润淋巴细胞（TILs）分级的PD-1和PD-L1作为结直肠癌预后和预测生物标志物的潜力
Curr Oncol. 2024 Nov 25;31(12):7476-7493. doi: 10.3390/curroncol31120552.
5
Nanobodies as innovative immune checkpoint modulators: advancing cancer immunotherapy.纳米抗体作为创新的免疫检查点调节剂：推动癌症免疫治疗
Med Oncol. 2024 Dec 24;42(1):36. doi: 10.1007/s12032-024-02588-y.
6
Immune Checkpoint Inhibitor-Induced Guillain Barre Syndrome: A Single-Institution Case Report and Narrative Review.免疫检查点抑制剂诱导的吉兰-巴雷综合征：单机构病例报告及叙述性综述
Cureus. 2024 Jun 1;16(6):e61489. doi: 10.7759/cureus.61489. eCollection 2024 Jun.
7
Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer.针对OX40胞外域的激动性二价人单链抗体片段-Fcγ融合抗体增强T细胞抗癌活性。
Vaccines (Basel). 2023 Dec 7;11(12):1826. doi: 10.3390/vaccines11121826.
8
Scleroderma Secondary to Pembrolizumab: A Case Report and Review of 19 Cases of Anti-PD-1-Induced Scleroderma.帕博利珠单抗继发硬皮病：一例报告及19例抗PD-1诱导的硬皮病病例回顾
Case Rep Oncol. 2023 Sep 6;16(1):846-856. doi: 10.1159/000533373. eCollection 2023 Jan-Dec.
9
Immunotherapy during the Immediate Perioperative Period: A Promising Approach against Metastatic Disease.即时围手术期免疫治疗：一种针对转移性疾病的有前途的方法。
Curr Oncol. 2023 Aug 7;30(8):7450-7477. doi: 10.3390/curroncol30080540.
10
Review of cancer therapies for the perioperative physician.围手术期医生的癌症治疗综述。
Perioper Med (Lond). 2023 Jun 13;12(1):25. doi: 10.1186/s13741-023-00315-1.
本文引用的文献
1
High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors.高突变负荷肿瘤与低突变负荷肿瘤、免疫原性热肿瘤与冷肿瘤，及其对免疫检查点抑制剂的反应。
J Immunother Cancer. 2018 Dec 27;6(1):157. doi: 10.1186/s40425-018-0479-7.
2
Methods of measurement for tumor mutational burden in tumor tissue.肿瘤组织中肿瘤突变负荷的测量方法。
Transl Lung Cancer Res. 2018 Dec;7(6):661-667. doi: 10.21037/tlcr.2018.08.02.
3
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.肿瘤突变负担作为免疫治疗生物标志物的发展：在肿瘤学临床中的应用。
Ann Oncol. 2019 Jan 1;30(1):44-56. doi: 10.1093/annonc/mdy495.
4
The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management.免疫检查点抑制剂的内分泌效应的当前认识及管理建议
JNCI Cancer Spectr. 2018 Jul;2(3):pky021. doi: 10.1093/jncics/pky021. Epub 2018 Jul 19.
5
Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer.程序性死亡配体-1 表达联合阳性评分在帕博利珠单抗治疗胃癌中的临床应用价值。
Arch Pathol Lab Med. 2019 Mar;143(3):330-337. doi: 10.5858/arpa.2018-0043-OA. Epub 2018 Jul 20.
6
Immune Checkpoint Inhibitor-Associated Myocarditis.免疫检查点抑制剂相关性心肌炎。
Oncologist. 2018 Aug;23(8):879-886. doi: 10.1634/theoncologist.2018-0130. Epub 2018 May 25.
7
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
8
Immunotherapy of melanoma.黑色素瘤的免疫疗法。
Contemp Oncol (Pozn). 2018 Mar;22(1A):61-67. doi: 10.5114/wo.2018.73889. Epub 2018 Mar 5.
9
Identifying and managing the adverse effects of immune checkpoint blockade.识别和管理免疫检查点阻断的不良反应。
J Thorac Dis. 2018 Feb;10(Suppl 3):S480-S489. doi: 10.21037/jtd.2018.01.111.
10
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.免疫检查点抑制剂治疗患者的心肌炎。
J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764. doi: 10.1016/j.jacc.2018.02.037. Epub 2018 Mar 19.
Zotero 插件